Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tumourprint

TUMOURPRINT SIGNED

High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 TUMOURPRINT project word cloud

Explore the words cloud of the TUMOURPRINT project. It provides you a very rough idea of what is the project "TUMOURPRINT" about.

animal    successfully    bioprinting    revolutionise    oncology    vascularity    capacity    collaborations    models    constructs    attrition    pharmaceutical    proper    printed    bioink    platform    universal    microenvironment    tissue    analytical    organisation    cell    predict    environment    combination    constitutes    pay    grown    countries    automated    completely    cellink    record    giants    humans    economic    3d    hydrogels    bioprinters    establishment    implications    first    2016    offers    global    commercialised    failed    unsatisfactory    drug    designed    robotics    cells    secured    serial    destructive    reproducible    rely    live    commercialise    unparalleled    trials    cancer    heterogeneity    specially    throughput    human    instructive    size    commercialized    exasperatingly    mono    disruptive    candidates    willingness    none    tumourprint    formulated    outcomes    precise    mimicking    scoring    ing    world    proposition    market    survival    printing    proven    bioinks    cultures    fold    company    fabricating    2d    fidel    rates    clinical    tumour    principally    track    optimal    ten    generations    drive    18    ethically    producing    commercialising   

Project "TUMOURPRINT" data sheet

The following table provides information about the project.

Coordinator		 CELLINK AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Sweden [SE]
 Project website https://cellink.com/global/
 Total cost 3˙500˙467 €
 EC max contribution 2˙450˙327 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2021-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLINK AB SE (GOTEBORG) coordinator 2˙450˙327.00

Map

 Project objective

CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical drug development and large-scale cancer research. Bioprinting constitutes the most advanced method for fabricating fidel tissue models, using live cells in combination with cell-instructive bioinks (specially formulated hydrogels that provide cells with an optimal environment for survival, growth and proper 3D development).

The high throughput platform - completely new to the market - is designed according to user needs. It will revolutionise drug development processes through serial production of fidel cancer models in an automated, precise and reproducible way. The platform offers unparalleled printing capacity and is integrated with robotics and none-destructive analytical methods capable of scoring drug responses in printed constructs.

Current oncology approaches principally rely on unsatisfactory 2D mono-cell cultures and animal models to predict outcomes in humans, resulting in exasperatingly high attrition rates of cancer drug candidates in clinical trials. The economic and ethically challenging implications of failed trials provide CELLINK with a unique value proposition to drive willingness-to-pay for their disruptive platform. TumourPrint will address today’s pharmaceutical challenges by producing tumour models capable of mimicking size, heterogeneity and vascularity of the human tumour microenvironment in a fidel way.

CELLINK has a proven track-record of successfully developing and commercialising products according to user needs; they developed the world’s first universal bioink, have commercialized three generations of bioprinters and optimised 18 cell-specific bioinks. Since the company’s establishment in 2016, CELLINK has commercialised its technology in over 40 countries, grown its organisation ten-fold and secured collaborations with several global pharmaceutical giants.

 Deliverables

List of deliverables.
Cancer cell lines selected Documents, reports 2019-11-28 17:30:38
10 hired employees Demonstrators, pilots, prototypes 2019-11-28 17:30:39

Take a look to the deliverables list in detail:  detailed list of TUMOURPRINT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUMOURPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUMOURPRINT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More